Literature DB >> 10512375

Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation.

R Singh1, N Alavi, A K Singh, D J Leehey.   

Abstract

Accumulation of mesangial matrix in diabetic nephropathy is caused by increased synthesis and decreased degradation. We have previously demonstrated that incubation in high-glucose medium decreases mesangial cell collagenase activity (Diabetes 44:929-935, 1995). Because angiotensin II (AII) is involved in the pathogenesis of diabetic nephropathy, the present studies were performed to determine if AII mediates glucose-induced 1) inhibition of mesangial collagenase activity, 2) mesangial matrix accumulation, and 3) in-crease in transforming growth factor (TGF)-beta1 secretion in mesangial cells. The direct effect of high glucose on AII generation in mesangial cells was also determined. Primary mesangial cells from normal Sprague-Dawley rats were used in all studies. Collagenase activity in cell medium was determined using three methods: 1) zymography; 2) quantitative assay using fluoresceinated gelatin as substrate; and 3) a new enzyme-linked immunosorbent assay (ELISA) that specifically measures 72-kDa collagenase (MMP-2), the principal collagenase synthesized by mesangial cells. Matrix accumulation was estimated by immunoperoxidase assay on cell layers using anti-glomerular basement membrane (GBM) antibodies. TGF-beta1 and AII levels were determined by ELISA. Exposure of mesangial cells to 30 mmol/l glucose (high glucose) vs. 5 mmol/glucose (normal glucose) for 5 days resulted in a significant decrease in collagenase activity (25%) that was normalized by 10(-4) mol/l losartan, a type 1 angiotensin II (AT1) receptor antagonist. High glucose increased anti-GBM binding compared with normal glucose; this effect of glucose was reversed by losartan. Incubation of cells with 30 mmol/l glucose increased total TGF-beta1 secretion, which was also normalized by losartan. Addition of AII (10(-6) mol/l) for 24 h to the culture medium inhibited collagenase activity by 33%; losartan (10(-4) mol/l) blocked this inhibition of enzyme activity. Also, AII decreased collagenase (MMP-2) levels but stimulated TGF-beta1 secretion in mesangial cells. Finally, glucose increased mesangial AII generation in a concentration-dependent manner, with incubation in 30 mmol/l glucose increasing AII by 25% compared with 5 mmol/l glucose. We conclude that glucose increases AII production by mesangial cells, which results in stimulation of TGF-beta1 secretion, decreased matrix degradation, and increased matrix accumulation. These effects of AII are mediated by the AT1 receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512375     DOI: 10.2337/diabetes.48.10.2066

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  31 in total

Review 1.  Peritoneal damage by peritoneal dialysis solutions.

Authors:  Takafumi Ito; Noriaki Yorioka
Journal:  Clin Exp Nephrol       Date:  2008-02-15       Impact factor: 2.801

Review 2.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

Review 3.  Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.

Authors:  Terry K W Ma; Kevin K H Kam; Bryan P Yan; Yat-Yin Lam
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells.

Authors:  Xiao C Li; Oscar A Carretero; Jia L Zhuo
Journal:  Biochem Pharmacol       Date:  2006-03-28       Impact factor: 5.858

Review 5.  Angiotensin receptor blockers in diabetic nephropathy.

Authors:  D A Price; N K Hollenberg
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 6.  Angiotensin II and the glomerulus: focus on diabetic kidney disease.

Authors:  James W Scholey
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

7.  Role of upstream stimulatory factor 2 in diabetic nephropathy.

Authors:  Shuxia Wang
Journal:  Front Biol (Beijing)       Date:  2015-05-13

8.  Ultrastructural alterations in capillaries of the diabetic hypertensive rat retina: protective effects of ACE inhibition.

Authors:  A A Dosso; E Rungger-Brändle; P M Leuenberger
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

9.  Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial.

Authors:  Piero Ruggenenti; Ilian Iliev; Marco Filipponi; Stefano Tadini; Annalisa Perna; Maria Ganeva; Bogdan Ene-Iordache; Paolo Cravedi; Roberto Trevisan; Antonio Bossi; Giuseppe Remuzzi
Journal:  J Ophthalmol       Date:  2010-06-10       Impact factor: 1.909

Review 10.  Advanced glycation end products, oxidative stress and diabetic nephropathy.

Authors:  Sho-Ichi Yamagishi; Takanori Matsui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.